Scott M Welford

Dr. Scott M Welford


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2009 in Molecular Cell
Verified
Journal Article
Closed access
XHXin Huang
Xin Huang
LDLianghao Ding
Lianghao Ding
KBKevin L. Bennewith
Kevin L. Bennewith
RTRicky T. Tong
Ricky T. Tong
SWScott M Welford
Scott M Welford
AGAmato J. Giaccia
Amato J. Giaccia

24 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
WDWeinan Du
Weinan Du
LZLuchang Zhang
Luchang Zhang
ABAdina Brett-Morris
Adina Brett-Morris
BABrittany Aguila
Brittany Aguila
JKJanos Kerner
Janos Kerner
SWScott M Welford
Scott M Welford
Clear cell renal cell carcinoma (ccRCC) is histologically defined by its lipid and glycogen-rich cytoplasmic deposits. Alterations in the VHL tumor suppressor stabilizing the hypoxia-inducible factors (HIFs) are the most prevalent molecular features of clear cell tumors. The significance of lipid deposition remains undefined. We describe the mechanism of lipid deposition in ccRCC by identifying the rate-limiting component of mitochondrial fatty acid transport, carnitine palmitoyltransferase 1A (CPT1A), as a direct HIF target gene. CPT1A is repressed by HIF1 and HIF2, reducing fatty acid transport into the mitochondria, and forcing fatty acids to lipid droplets for storage. Droplet formation occurs independent of lipid source, but only when CPT1A is repressed. Functionally, repression of CPT1A is critical for tumor formation, as elevated CPT1A expression limits tumor growth. In human tumors, CPT1A expression and activity are decreased versus normal kidney; and poor patient outcome associates with lower expression of CPT1A in tumors in TCGA. Together, our studies identify HIF control of fatty acid metabolism as essential for ccRCC tumorigenesis.

3 October 2022 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
STSze Kiat Tan
Sze Kiat Tan
HHHelen Y. Hougen
Helen Y. Hougen
JMJaime R. Merchan
Jaime R. Merchan
MGMark L. Gonzalgo
Mark L. Gonzalgo
SWScott M Welford
Scott M Welford

23 March 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
STSze Kiat Tan
Sze Kiat Tan
IMIqbal Mahmud
Iqbal Mahmud
FFFlavia Fontanesi
Flavia Fontanesi
MPMichelle Puchowicz
Michelle Puchowicz
CNChase K.A. Neumann
Chase K.A. Neumann
SWScott M Welford
Scott M Welford
Clear cell renal cell carcinoma (ccRCC) is characterized by accumulation of neutral lipids and adipogenic transdifferentiation. We assessed adipokine expression in ccRCC and found that tumor tissues and patient plasma exhibit obesity-dependent elevations of the adipokine chemerin. Attenuation of chemerin by several approaches led to significant reduction in lipid deposition and impairment of tumor cell growth in vitro and in vivo. A multi-omics approach revealed that chemerin suppresses fatty acid oxidation, preventing ferroptosis, and maintains fatty acid levels that activate hypoxia-inducible factor 2α expression. The lipid coenzyme Q and mitochondrial complex IV, whose biogeneses are lipid-dependent, were found to be decreased after chemerin inhibition, contributing to lipid reactive oxygen species production. Monoclonal antibody targeting chemerin led to reduced lipid storage and diminished tumor growth, demonstrating translational potential of chemerin inhibition. Collectively, the results suggest that obesity and tumor cells contribute to ccRCC through the expression of chemerin, which is indispensable in ccRCC biology. Significance: Identification of a hypoxia-inducible factor–dependent adipokine that prevents fatty acid oxidation and causes escape from ferroptosis highlights a critical metabolic dependency unique in the clear cell subtype of kidney cancer. Targeting lipid metabolism via inhibition of a soluble factor is a promising pharmacologic approach to expand therapeutic strategies for patients with ccRCC. See related commentary by Reznik et al., p. 1879. This article is highlighted in the In This Issue feature, p. 1861

15 May 2011 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
SWScott M Welford
Scott M Welford
AGAmato J. Giaccia
Amato J. Giaccia
Cellular senescence has emerged as a biological response to two major pathophysiological states of our being: cancer and aging. In the course of the transformation of a normal cell to a cancerous cell, senescence is frequently induced to suppress tumor development. In aged individuals, senescence is found in cells that have exhausted their replication potential. The similarity in these responses suggests that understanding how senescence is mediated can provide insight into both cancer and aging. One environmental factor that is implicated in both of these states is tissue hypoxia, which increases with aging and can inhibit senescence. Hypoxia is particularly important in normal physiology to maintain the stem cell niche; but at the same time, hypoxic inhibition of an essential tumor suppressor response can theoretically contribute to cancer initiation. Mol Cancer Res; 9(5); 538–44. ©2011 AACR.

30 November 2014 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ABAdina Brett-Morris
Adina Brett-Morris
BWBradley M. Wright
Bradley M. Wright
YSYuji Seo
Yuji Seo
VPVinay Pasupuleti
Vinay Pasupuleti
JZJunran Zhang
Junran Zhang
SWScott M Welford
Scott M Welford
Glioblastoma multiforme (GBM) is the most common and severe form of brain cancer. The median survival time of patients is approximately 12 months due to poor responses to surgery and chemoradiation. To understand the mechanisms involved in radioresistance, we conducted a genetic screen using an shRNA library to identify genes in which inhibition would sensitize cells to radiation. The results were cross-referenced with the Oncomine and Rembrandt databases to focus on genes that are highly expressed in GBM tumors and associated with poor patient outcomes. Spermidine/spermine-N1-acetyltransferase 1 (SAT1), an enzyme involved in polyamine catabolism, was identified as a gene that promotes resistance to ionizing radiation (IR), is overexpressed in brain tumors, and correlates with poor outcomes. Knockdown of SAT1 using shRNA and siRNA approaches in multiple cell and neurosphere lines resulted in sensitization of GBM cells to radiation in colony formation assays and tumors, and decreased tumorigenesis in vivo. Radiosensitization occurred specifically in G2–M and S phases, suggesting a role for SAT1 in homologous recombination (HR) that was confirmed in a DR-GFP reporter system. Mechanistically, we found that SAT1 promotes acetylation of histone H3, suggesting a new role of SAT1 in chromatin remodeling and regulation of gene expression. In particular, SAT1 depletion led to a dramatic reduction in BRCA1 expression, explaining decreased HR capacity. Our findings suggest that the biologic significance of elevated SAT1 expression in GBM lies in its contribution to cell radioresistance and that SAT1 may potentially be a therapeutic target to sensitize GBM to cancer therapies. Cancer Res; 74(23); 6925–34. ©2014 AACR.